Literature DB >> 33553607

Enhancing endocrine therapy activity via fasting cycles: biological rationale and clinical feasibility.

Irene Caffa1,2, Alessio Nencioni1,2.   

Abstract

We found that periodic fasting increases the anti-cancer activity of endocrine agents used to treat hormone receptor-positive breast cancer and delays acquired resistance to them by reducing blood leptin, insulin and insulin-like growth factor 1 (IGF1). Our work supports further clinical studies of fasting as an adjuvant to endocrine agents in breast cancer patients.
© 2020 Taylor & Francis Group, LLC.

Entities:  

Keywords:  AKT; Breast cancer; diet; endocrine therapy; fasting

Year:  2020        PMID： 33553607      PMCID： PMC7849721          DOI： 10.1080/23723556.2020.1853492

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  9 in total

Review 1.  Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.

Authors:  Kazuhiro Araki; Yasuo Miyoshi
Journal:  Breast Cancer       Date:  2017-10-31       Impact factor: 4.239

2.  ESPEN guidelines on nutrition in cancer patients.

Authors:  Jann Arends; Patrick Bachmann; Vickie Baracos; Nicole Barthelemy; Hartmut Bertz; Federico Bozzetti; Ken Fearon; Elisabeth Hütterer; Elizabeth Isenring; Stein Kaasa; Zeljko Krznaric; Barry Laird; Maria Larsson; Alessandro Laviano; Stefan Mühlebach; Maurizio Muscaritoli; Line Oldervoll; Paula Ravasco; Tora Solheim; Florian Strasser; Marian de van der Schueren; Jean-Charles Preiser
Journal:  Clin Nutr       Date:  2016-08-06       Impact factor: 7.324

3.  CDK4/6 Inhibitors in Combination With Hormone Therapy for HR+/HER2- Advanced Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Authors:  Yunfu Deng; Guangzhi Ma; Wen Li; Ting Wang; Yaqin Zhao; Qiang Wu
Journal:  Clin Breast Cancer       Date:  2018-05-04       Impact factor: 3.225

4.  Role of leptin in the neuroendocrine response to fasting.

Authors:  R S Ahima; D Prabakaran; C Mantzoros; D Qu; B Lowell; E Maratos-Flier; J S Flier
Journal:  Nature       Date:  1996-07-18       Impact factor: 49.962

Review 5.  Fasting and cancer: molecular mechanisms and clinical application.

Authors:  Alessio Nencioni; Irene Caffa; Salvatore Cortellino; Valter D Longo
Journal:  Nat Rev Cancer       Date:  2018-11       Impact factor: 60.716

Review 6.  Molecular mechanisms of leptin and adiponectin in breast cancer.

Authors:  Thierry Jardé; Stéphane Perrier; Marie-Paule Vasson; Florence Caldefie-Chézet
Journal:  Eur J Cancer       Date:  2011-01       Impact factor: 9.162

7.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

8.  Fasting-mimicking diet and hormone therapy induce breast cancer regression.

Authors:  Irene Caffa; Vanessa Spagnolo; Valter D Longo; Alessio Nencioni; Claudio Vernieri; Francesca Valdemarin; Pamela Becherini; Min Wei; Sebastian Brandhorst; Chiara Zucal; Else Driehuis; Lorenzo Ferrando; Francesco Piacente; Alberto Tagliafico; Michele Cilli; Luca Mastracci; Valerio G Vellone; Silvano Piazza; Anna Laura Cremonini; Raffaella Gradaschi; Carolina Mantero; Mario Passalacqua; Alberto Ballestrero; Gabriele Zoppoli; Michele Cea; Annalisa Arrighi; Patrizio Odetti; Fiammetta Monacelli; Giulia Salvadori; Salvatore Cortellino; Hans Clevers; Filippo De Braud; Samir G Sukkar; Alessandro Provenzani
Journal:  Nature       Date:  2020-07-15       Impact factor: 49.962

9.  Molecular mechanisms of tamoxifen-associated endometrial cancer (Review).

Authors:  Rong Hu; Leena Hilakivi-Clarke; Robert Clarke
Journal:  Oncol Lett       Date:  2015-02-12       Impact factor: 2.967
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.